Literature DB >> 7858872

Evidence for P2-purinoceptor-mediated inhibition of noradrenaline release in rat brain cortex.

I von Kügelgen1, L Späth, K Starke.   

Abstract

1. Some postganglionic sympathetic axons possess P2Y-like P2-purinoceptors which, when activated, decrease the release of noradrenaline. We examined the question of whether such receptors also occur at the noradrenergic axons in the rat brain cortex. Slices of the brain cortex were preincubated with [3H]-noradrenaline, then superfused with medium containing desipramine (1 microM) and stimulated electrically, in most experiments by trains of 4 pulses/100 Hz. 2. The selective adenosine A1-receptor agonist, N6-cyclopentyl-adenosine (CPA; 0.03-3 microM) as well as the non-subtype-selective agonist 5'-N-ethylcarboxamido-adenosine (NECA; 0.3-3 microM) reduced the evoked overflow of tritium, whereas the adenosine A2a-receptor agonist, 2-p-(2-carbonylethyl)-phenethylamino-5'-N-ethylcarboxamido-a denosine (CGS-21680; 0.003-30 microM) and the adenosine A3-receptor agonist N6-2-(4-aminophenyl)ethyl-adenosine (APNEA; 0.03-3 microM) caused no change. Of the nucleotides tested, ATP (30-300 microM), adenosine-5'-O-(3-thiotriphosphate) (ATP gamma S; 30-300 microM), adenosine-5'-O-(2-thiodiphosphate) (ADP beta S; 30-300 microM), P1,P4-di(adenosine-5')-tetraphosphate (Ap4A; 30-300 microM) and the preferential P2Y-purinoceptor agonist, 2-methylthio-ATP (300 microM) decreased the evoked overflow of tritium. The P2X-purinoceptor agonist, alpha,beta-methylene-ATP (3-300 microM) caused no change. 3. The A1-selective antagonist, 8-cyclopentyl-1,3-dipropylxanthine (DPCPX; 10 nM) attenuated the effects of the nucleosides CPA (apparent pKB value 9.8) and NECA as well as of the nucleotides ATP (apparent pKB 9.3), ATP gamma S (apparent pKB 9.2) and ADP beta S (apparent pKB 8.7). CGS-21680 and APNEA were ineffective also in the presence of DPCPX. The A2-selective antagonist 1,3-dipropyl-8-(3,4-dimethoxystyryl)-7-methylxanthine (KF-17837) reduced the effects of CPA, NECA and ATP gamma S only when given at a concentration of 300 nM but not at 1O nM.4. The P2-purinoceptor antagonists, suramin (300 micro M), reactive blue 2 (30 micro M) and cibacron blue 3GA(30 micro M) did not change the effect of CPA. Suramin and cibacron blue 3GA shifted the concentration response curve of ATP gamma S to the right (apparent pKB values 3.7 and 5.0, respectively). Reactive blue 2 also attenuated the effect of ATPyS, and cibacron blue 3GA attenuated the effect of ATP, but in these cases the agonist concentration-response curves were not shifted to the right. There was no antagonistic effect of suramin against ATP and ADP beta S.5. The results indicate that rat cerebrocortical noradrenergic axons possess, in addition to the knownadenosine Al-receptor, a separate purinoceptor for nucleotides (P2) which, in contrast to the Al-receptor,is blocked by suramin, reactive blue 2 and cibacron blue 3GA. Nucleotides such as ATP and ATP gamma S activate both receptors. Inconsistencies in antagonist effects against nucleotides are probably due to this activation of two receptors. The presynaptic P2-purinoceptor is P2Y-like, as it is in the peripheral sympathetic nervous system.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7858872      PMCID: PMC1510427          DOI: 10.1111/j.1476-5381.1994.tb17066.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  62 in total

1.  Pre- and post-junctional effects of adenosine triphosphate on noradrenergic transmission in the rabbit ear artery.

Authors:  H Miyahara; H Suzuki
Journal:  J Physiol       Date:  1987-08       Impact factor: 5.182

2.  8-Cyclopentyl-1,3-dipropylxanthine (DPCPX)--a selective high affinity antagonist radioligand for A1 adenosine receptors.

Authors:  M J Lohse; K N Klotz; J Lindenborn-Fotinos; M Reddington; U Schwabe; R A Olsson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-08       Impact factor: 3.000

Review 3.  Modulation of neurotransmitter release by presynaptic autoreceptors.

Authors:  K Starke; M Göthert; H Kilbinger
Journal:  Physiol Rev       Date:  1989-07       Impact factor: 37.312

4.  Suramin: a reversible P2-purinoceptor antagonist in the mouse vas deferens.

Authors:  P M Dunn; A G Blakeley
Journal:  Br J Pharmacol       Date:  1988-02       Impact factor: 8.739

5.  Evidence against a functional link between noradrenaline uptake mechanisms and presynaptic alpha-2 adrenoceptors.

Authors:  G Zier; H Drobny; B Valenta; E A Singer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-01       Impact factor: 3.000

Review 6.  How does adenosine inhibit transmitter release?

Authors:  B B Fredholm; T V Dunwiddie
Journal:  Trends Pharmacol Sci       Date:  1988-04       Impact factor: 14.819

7.  Characterization of prejunctional purinoceptors on adrenergic nerves of the rat caudal artery.

Authors:  K Shinozuka; R A Bjur; D P Westfall
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-09       Impact factor: 3.000

8.  Axon terminal P2-purinoceptors in feedback control of sympathetic transmitter release.

Authors:  I von Kügelgen; K Kurz; K Starke
Journal:  Neuroscience       Date:  1993-09       Impact factor: 3.590

Review 9.  G protein-coupled receptors for ATP and other nucleotides: a new receptor family.

Authors:  E A Barnard; G Burnstock; T E Webb
Journal:  Trends Pharmacol Sci       Date:  1994-03       Impact factor: 14.819

10.  Absence of P2-purinoceptors in hippocampal pathways.

Authors:  T W Stone; N J Cusack
Journal:  Br J Pharmacol       Date:  1989-06       Impact factor: 8.739

View more
  20 in total

1.  An interaction between ATP and high K+: mutual impairment of ATP- and high K(+)-evoked [Ca2+]i increase in NG 108-15 cells.

Authors:  Sheng-Nan Li; Gang Hu; Manfred Bräter; Klaus Andreas; Ursula Ravens
Journal:  Neurochem Res       Date:  2002-06       Impact factor: 3.996

2.  Characterization and tissue location of the neural adenosine receptor in the rat ileum.

Authors:  I M Coupar
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

Review 3.  Functions of neuronal P2Y receptors.

Authors:  Simon Hussl; Stefan Boehm
Journal:  Pflugers Arch       Date:  2006-05-10       Impact factor: 3.657

4.  Functional characterization of adenosine receptors in the nucleus tractus solitarius mediating hypotensive responses in the rat.

Authors:  P J White; R B Rose'Meyer; W Hope
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

5.  Cultured chick sympathetic neurons: modulation of electrically evoked noradrenaline release by P2-purinoceptors.

Authors:  C Allgaier; H Wellmann; A Schobert; I von Kügelgen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-07       Impact factor: 3.000

6.  P2 receptor excitation of rodent hypoglossal motoneuron activity in vitro and in vivo: a molecular physiological analysis.

Authors:  G D Funk; R Kanjhan; C Walsh; J Lipski; A M Comer; M A Parkis; G D Housley
Journal:  J Neurosci       Date:  1997-08-15       Impact factor: 6.167

7.  Purinoceptor modulation of noradrenaline release in rat tail artery: tonic modulation mediated by inhibitory P2Y- and facilitatory A2A-purinoceptors.

Authors:  J Gonçalves; G Queiroz
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

8.  P2Y receptor regulation of cultured rat cerebral cortical cells: calcium responses and mRNA expression in neurons and glia.

Authors:  Gillian C Bennett; Anthony P D W Ford; Jacqueline A M Smith; Caroline J Emmett; Tania E Webb; Michael R Boarder
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

9.  Diadenosine polyphosphates evoke Ca2+ transients in guinea-pig brain via receptors distinct from those for ATP.

Authors:  J Pintor; J A Puche; J Gualix; C H Hoyle; M T Miras-Portugal
Journal:  J Physiol       Date:  1997-10-15       Impact factor: 5.182

Review 10.  P2Y receptors in Alzheimer's disease.

Authors:  Laurie Erb; Chen Cao; Deepa Ajit; Gary A Weisman
Journal:  Biol Cell       Date:  2014-10-13       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.